Emerging evidence has demonstrated that dysregulation of M6A modulators, such as YTHDF1, METTL3, and FTO, plays an important role in the regulation of the occurrence, progression, and immune microenvironment of malignant tumors [14–19]. The gene discussed is METTL3; the disease is cancer.